ArticlePLoS pathogens2022
The emergence and worldwide spread of the species Trichophyton indotineae causing difficult-to-treat dermatophytosis: A new challenge in the management of dermatophytosis.
Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Mapping the Global Spread of T. indotineae: An Update on Antifungal Resistance, Mutations, and Strategies for Effective Management.Mycopathologia · 2024Pooled it
- Dual PCR-Sanger Sequencing Assay for Simultaneous sqle-Based Identification and Resistance Detection in Trichophyton Species.Emerging infectious diseases · 2026Article
- Knowledge and diagnostic practices for extensive recalcitrant dermatophytosis due toNew microbes and new infections · 2026Article
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
- The emergence of superficial dermatophytosis due toJournal of clinical microbiology · 2026Article
- Article
- Molecular Characterization and Preliminary NGS Profiling of Terbinafine-ResistantPathogens (Basel, Switzerland) · 2026Article
- Global Emergence ofInfection and drug resistance · 2026Review
- Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Oo-No: Ophidiomyces ophidiicola-bacterial interactions and the role of skin lipids in development of ophidiomycosis.PLoS pathogens · 2026Article
- Rapid emergence ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Update on the epidemiology of dermatophytosis in Isfahan, Iran over the past decade.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Genomic epidemiology and antifungal resistance of emergingEmerging microbes & infections · 2025Article
- Does the use of topical azoles have an impact on antifungal resistance?The Journal of antimicrobial chemotherapy · 2025Article
- Integrating Machine Learning and Molecular Methods forPathogens (Basel, Switzerland) · 2025Article
- Article
- In vitro activity of nanoliposomal amphotericin B against terbinafine-resistant Trichophyton indotineae isolates.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte,Journal of clinical microbiology · 2025Review
- The Fungal Kingdom as a Rosetta Stone for biological discovery.Current biology : CB · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.